Trusted Resources: News & Meetings
Latest announcements and gatherings
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).
RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes.
BookmarkRelated Content
-
Evidence of Treatment Benefits in Patients With Mucopolysaccharidosis Type I-Hurler in Long-Term Follow-Up Using a N...We developed a brain and spine magnetic ...
-
Burden of Morbidity After Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor...Survival after blood or marrow transplan...
-
Surgical Management of an Aortic Root Dilatation in a Patient Suffering From Hunter SyndromeHunter syndrome is a rare disease leadin...
-
Newborn Screening of Mucopolysaccharidosis Type IMucopolysaccharidosis type I (MPS I), a ...
-
Enzyme Replacement Therapy With Galsulfase for Mucopolysaccharidosis Type VIMucopolysaccharidosis type VI (MPS VI) o...
-
Quantitative Brain MRI Morphology in Severe and Attenuated Forms of Mucopolysaccharidosis Type ITo assess our hypothesis that brain macr...
-
Mucopolysaccharidoses Type I Gene TherapyMucopolysaccharidoses type I (MPS I) is ...
Powered by
